Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 164, Issue 3, pp 382–385 | Cite as

Connection between Parameters of Erythron System and Myelofibrosis during Chronic Myeloleukemia, Multiply Mieloma, and Chronic Lymphatic Leukemia

  • T. Yu. Dolgikh
  • E. V. Sholenberg
  • I. V. Kachesov
  • S. R. Senchukova
Article
  • 18 Downloads

Clinical and morphological investigation of myelofibrosis was performed in patients with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia by analyzing the morphometric parameters of trepan-biopsy material. The correlation between changes in the parameters of erythron system and distribution of myelofibrosis were analyzed. In patients with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia, the maximum suppression of the erythron was observed against the background of severe myelofibrosis. The degree of erythron inhibition correlated with distribution of the fibrous tissue in the bone marrow. In patients with onset of chronic phase of chronic myeloid leukemia and active phase of multiple myeloma, the total number of erythroid cells was lower than in active phase of chronic lymphocytic leukemia irrespective of the degree of myelofibrosis. Erythrocyte count and hemoglobin content in the peripheral blood were lower in patients with multiple myeloma and chronic lymphocytic leukemia in comparison with the corresponding parameters in patients with chronic myeloid leukemia irrespective of the severity of myelofibrosis.

Key Words

chronic myeloid leukemia multiple myeloma chronic lymphocytic leukemia myelofibrosis erythron system 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Anemia of Chronic Disease. Manual for Hematology. Vol. 3. Vorob’ev AI, ed. Moscow, 2005. P. 313-322. Russian.Google Scholar
  2. 2.
    Babicheva LG, Poddubnaya IV. Anemia and methods of its correction in cancer patients. Sovremen. Onkol. 2010;(3):89-93. Russian.Google Scholar
  3. 3.
    Dolgikh TY, Sholenberg EV, Kachesov IV, Domnikova NP, Klinnikova MG. Clinical Morphological Studies of Myelofibrosis with Different Types of Bone Marrow Involvement in Patients with Chronic Lymphocytic Leukemia. Bull. Exp. Biol. Med. 2016;161(3):408-411.CrossRefPubMedGoogle Scholar
  4. 4.
    Domnikova NP, Dolgikh TYu. Prevalence of myelofibrosis in chronic myeloid leukemia, multiple myeloma and chronic lymphocytic leukemia in different phases of diseases. Sib. Nauch. Med. Zh. 2016;36(5):53-57. Russian.Google Scholar
  5. 5.
    Domnikova NP, Nepomnyashchikh GI, Dolgikh TYu, Petrusenko EE, Kachesov IV. Morphological study of trephine biopsies in non-Hodgkin’s lymphomas. Sib. Onkol. Zh. 2011;(3):45-50. Russian.Google Scholar
  6. 6.
    Mendeleeva LP, Votyakova OM, Pokrovskaya OS, Rekhtina IG, Bessmel’tsev SS, Golubeva ME, Darskaya EI, Zagoskina TP, Zinina EE, Kaplanov KD, Konstantinova TS, Kryuchkova IV, Medvedeva NV, Motorin SV, Pospelova TI, Ryzhko VV, Samoilova OS, Urnova ES, Savchenko VG. National clinical guidelines for the diagnosis and treatment of multiple myeloma. Gematol. Transfuziol. 2014;59(S3):2-24. Russian.Google Scholar
  7. 7.
    Pavlov AD, Morshchakova EF, Rumyantsev AG. Erythropoiesis, Erythropoietin, and Iron. Moscow, 2011. Russian.Google Scholar
  8. 8.
    Treatment Protocols for Blood Diseases. Savchenko VG, ed. Moscow, 2012. Russian.Google Scholar
  9. 9.
    Saraeva NO. Mechanisms of anemia development in hematological malignancies. Gematol. Transfuziol. 2007;52(1):31-37. Russian.Google Scholar
  10. 10.
    Saraeva NO, Gorokhova LA, Khoroshih OV, Musinzeva JaA, Zagorodnaya AN. Mechanisms of development of anemia at patients with a multiple myeloma. Sib. Med. Zh. (Irkutsk). 2006;65(7):28-30. Russian.Google Scholar
  11. 11.
    State of Cancer Care in Russia in 2015. Karpin AD, Starinskii VV, Petrova GV, eds. Moscow, 2016. Russian.Google Scholar
  12. 12.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.Google Scholar
  13. 13.
    Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000;95(9):2786-2792.PubMedGoogle Scholar
  14. 14.
    Tadmor T, Shvidel L, Aviv A, Ruchlemer R, Bairey O, Yuklea M, Herishanu Y, Braester A, Rahimi-Levene N, Vernea F, Ben-Ezra J, Bejar J, Polliack A; Israeli CLL Study Group. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications. Cancer. 2013;119(10):1853-1859.Google Scholar
  15. 15.
    Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128-1132.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • T. Yu. Dolgikh
    • 1
  • E. V. Sholenberg
    • 1
  • I. V. Kachesov
    • 1
  • S. R. Senchukova
    • 1
  1. 1.Institute of Molecular Pathology and PathomorphologyNovosibirskRussia

Personalised recommendations